종양 보도자료 - 뉴스와이어 https://www.newswire.co.kr/?md=A01&cat=1000&cat1=1010 종양 보도자료 - 뉴스와이어 RSS 서비스 Tue, 09 Jun 2026 10:58:06 +0900 Copyright (c) 2004~2026 Korea Newswire All rights reserved gichan2@newswire.co.kr ko Newswire https://static.newswire.co.kr/images/logo/logo_rss.png https://www.newswire.co.kr Newswire - 보도자료 통신사 뉴스와이어 <![CDATA[비원 메디신스, ASCO 2026에서 새로운 데이터로 고형종양 파이프라인 가속화 강조]]> https://www.newswire.co.kr/newsRead.php?no=1035776&sourceType=rss 종양 Wed, 03 Jun 2026 13:00:00 +0900 <![CDATA[BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026]]> https://www.newswire.co.kr/newsRead.php?no=1035775&sourceType=rss 종양 Wed, 03 Jun 2026 13:00:00 +0900 <![CDATA[비원 메디신스, ASCO 2026에서 브루킨사의 78개월 데이터 발표… CLL 장기 질환 조절 기준 확립]]> https://www.newswire.co.kr/newsRead.php?no=1035632&sourceType=rss 종양 Mon, 01 Jun 2026 15:35:00 +0900 <![CDATA[BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026]]> https://www.newswire.co.kr/newsRead.php?no=1035631&sourceType=rss 종양 Mon, 01 Jun 2026 15:35:00 +0900 <![CDATA[비원 메디신스, HERIZON-GEA 3상 임상시험 데이터의 NEJM 게재 및 ASCO 2026 발표 공개]]> https://www.newswire.co.kr/newsRead.php?no=1035489&sourceType=rss 종양 Fri, 29 May 2026 12:00:00 +0900 <![CDATA[BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026]]> https://www.newswire.co.kr/newsRead.php?no=1035483&sourceType=rss 종양 Fri, 29 May 2026 12:00:00 +0900 <![CDATA[브레누스 파마, MSS 전이성 대장암 대상 STC-1010 임상시험계획 FDA 승인 발표]]> https://www.newswire.co.kr/newsRead.php?no=1035472&sourceType=rss 종양 Fri, 29 May 2026 10:00:00 +0900 <![CDATA[비원 메디신스, ASCO 및 EHA 2026에서 60개 이상의 초록 발표로 종양학 분야 선도적 행보]]> https://www.newswire.co.kr/newsRead.php?no=1035225&sourceType=rss 종양 Tue, 26 May 2026 16:00:00 +0900 <![CDATA[BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts]]> https://www.newswire.co.kr/newsRead.php?no=1035224&sourceType=rss 종양 Tue, 26 May 2026 16:00:00 +0900 <![CDATA[Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer]]> https://www.newswire.co.kr/newsRead.php?no=1035057&sourceType=rss 종양 Fri, 22 May 2026 10:47:58 +0900 <![CDATA[비원 메디신스, 축구계의 전설 팀 하워드와 함께 글로벌 암 인식 캠페인 ‘한 번의 선방이 모든 것을 바꾼다’ 출범]]> https://www.newswire.co.kr/newsRead.php?no=1035000&sourceType=rss 종양 Thu, 21 May 2026 15:30:00 +0900 <![CDATA[BeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim Howard]]> https://www.newswire.co.kr/newsRead.php?no=1034999&sourceType=rss 종양 SAN CARLOS, Calif.--(Business Wire/Korea Newswire)--BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today launched One Save Changes Everything , a campaign that uses soccer as a lens to recognize...]]> Thu, 21 May 2026 15:30:00 +0900 <![CDATA[비원 메디신스 BEQALZI™(sonrotoclax), 미국 FDA로부터 재발성·불응성 외투세포림프종 치료 위한 최초이자 유일한 BCL2 억제제로 승인 획득]]> https://www.newswire.co.kr/newsRead.php?no=1034559&sourceType=rss 종양 Fri, 15 May 2026 15:30:00 +0900 <![CDATA[BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma]]> https://www.newswire.co.kr/newsRead.php?no=1034558&sourceType=rss 종양 SAN CARLOS, Calif.--(Business Wire/Korea Newswire)--BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approv...]]> Fri, 15 May 2026 15:30:00 +0900 <![CDATA[비원 메디신스, 2026년 1분기 재무 결과 및 비즈니스 업데이트 발표]]> https://www.newswire.co.kr/newsRead.php?no=1034094&sourceType=rss 종양 Sun, 10 May 2026 15:25:00 +0900